Primary Care of Patients With Cancer

Rebecca Eary, DO, MPH
Esther Ho, MD
Bijal A. Balasubramanian, MBBS, PhD

American Family Physician. 2026;114(4):393-411.

Author Disclosure: No relevant financial relationships.

This clinical content conforms to AAFP criteria for CME.

Family physicians are uniquely positioned to provide comprehensive care of patients across the cancer care continuum. Their longitudinal relationship with patients allows them to address cancer-related issues in addition to chronic disease management, preventive care, psychosocial needs, and caregiver support. Maintaining awareness of a patient's cancer diagnosis and related treatment is essential for evaluating new symptoms, recognizing treatment-related adverse effects, and identifying potential oncologic emergencies. Cancer treatment often complicates management of existing chronic illnesses, requiring close monitoring, medication adjustments, and attention to lifestyle factors and nutritional status. Goals of diabetes management include optimal glycemic control to prevent delays in oncologic surgeries, impaired wound healing, and difficulty in managing chemotherapy. Screening for cardiovascular disease should be performed for patients with cancer and known cardiac risk factors or oncologic treatment exposures known to cause cardiac complications. Consistent physical activity is recommended during cancer treatment to improve quality of life. Family physicians frequently serve as the first point of contact when patients experience adverse effects or complications from cancer therapies, many of which can affect physical function, mental health, and quality of life. Effective coordination between oncologists and family physicians is essential to ensure patients receive holistic, person-centered care.

Approximately 40% of men and women in the United States will have cancer in their lifetime, and most at some point will access medical care in primary care settings.1–4 The National Cancer Institute defines cancer survivorship as the continuum from diagnosis to the end of life.3,5 The continuous and trusted relationship that family physicians build with their patients uniquely positions them to provide whole-person care from initial diagnosis to treatment and survivorship.

Primary care physicians should be recognized as integral members of the care team, given their central role in managing the overall health of patients across the cancer continuum. Evidence consistently shows that regardless of cancer status, patients who maintain an ongoing relationship with a primary care physician experience lower mortality rates from cancer, cardiovascular disease (CVD), and respiratory conditions compared with patients who rely solely on specialty care.6 Stronger connections to primary care are associated with greater adherence to preventive health measures, including routine cancer screenings.7

It is critical that family physicians maintain awareness of which patients have cancer or a history of cancer, as well as treatment received, even if it is broad (eg, history of chemotherapy or radiation). Research shows that documentation rates of cancer history are as low as 7%, which may leave family physicians unaware of important medical history.8 Table 1 lists suggested questions for obtaining an oncologic history.2,9,10

This article focuses on care of patients who currently have cancer. The care of patients with a history of cancer was covered previously in American Family Physician.11

WHAT'S NEW ON THIS TOPIC

Primary Care of Patients With Cancer
A large national survey found that more than 90% of primary care physicians caring for patients with cancer manage comorbid chronic conditions, pain, psychological distress, and aspects of end-of-life care for patients receiving cancer therapy.
In a large national sample of more than 30,000 cancer survivors, patients with a history of cancer had a significantly higher prevalence of diabetes, hypertension, kidney and liver disease, and morbid obesity than those without cancer.
Eating a predominantly plant-based diet, completing at least 30 minutes of moderate-intensity exercise 5 days per week, and maintaining a body mass index less than 25 kg/m2 are associated with lower risk of cancer recurrence and mortality, especially in survivors of colorectal, breast, and prostate cancers.

REBECCA EARY, DO, MPH, is an associate professor in the Department of Family and Community Medicine at University of Texas (UT) Southwestern Medical School, Dallas.

ESTHER HO, MD, is an adjunct associate professor in the Department of Family and Community Medicine at UT Southwestern Medical School, Dallas.

BIJAL A. BALASUBRAMANIAN, MBBS, PhD, is a professor and Rockwell Distinguished Chair in Society and Health in the Department of Epidemiology at the UTHealth Houston School of Public Health and the UTHealth Houston Institute for Implementation Science, Houston.

Address correspondence to Rebecca Eary, DO, MPH, at rebecca.eary@utsouthwestern.edu.

Author Disclosure: No relevant financial relationships.

  1. 1.Nathan PC, et al. Medical care in long-term survivors of childhood cancer. J Clin Oncol. 2008;26(27):4401-4409.
  2. 2.National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: cancer of any site. Accessed May 1, 2026. https://seer.cancer.gov/statfacts/html/all.html​
  3. 3.National Cancer Institute. Survivorship. NCI dictionary of cancer terms. Accessed May 1, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/survivorship​
  4. 4.Pinheiro LC, et al. Nearly all cancer survivors return to primary care. J Am Board Fam Med. 2022;35(4):827-832.
  5. 5.Jiang C, et al. Chronic comorbid conditions among adult cancer survivors in the United States. Cancer. 2022;128(4):828-838.
  6. 6.Basu S, et al. Association of primary care physician supply with population mortality in the United States, 2005–2015. JAMA Intern Med. 2019;179(4):506-514.
  7. 7.Atlas SJ, et al. Patient-physician connectedness and quality of primary care. Ann Intern Med. 2009;150(5):325-335.
  8. 8.Booker Q, et al. Patient history of cancer in primary care: a closer look among cancer survivors with chronic conditions in federally qualified health centers. BMC Prim Care. 2025;26(1):39.
  9. 9.Shapiro CL, et al. ReCAP: ASCO core curriculum for cancer survivorship education. J Oncol Pract. 2016;12(2):145-e117.
  10. 10.Rosenzweig MQ, et al. The history and physical in cancer care. J Adv Pract Oncol. 2014;5(4):262-268.
  11. 11.Carek S, et al. Primary care of adult cancer survivors. Am Fam Physician. 2024;110(1):37-44.
  12. 12.Klabunde CN, et al. The role of primary care physicians in cancer care. J Gen Intern Med. 2009;24(9):1029-1036.
  13. 13.Oeffinger KC, et al. Oncology, primary care, and survivorship: time for onco-primary care?. JCO Oncol Pract. 2025;21(6):735-738.
  14. 14.Rabow MW, et al. Beyond breaking bad news: how to help patients who suffer. West J Med. 1999;171(4):260-263.
  15. 15.Narayanan V, et al. ‘BREAKS’ protocol for breaking bad news. Indian J Palliat Care. 2010;16(2):61-65.
  16. 16.Baile WF, et al. SPIKES – a six-step protocol for delivering bad news: application to the patient with cancer. Oncologist. 2000;5(4):302-311.
  17. 17.Stiefel F, et al. Communication and support of patients and caregivers in chronic cancer care. ESMO Open. 2024;9(7):103496.
  18. 18.Ariadne Labs, Dana-Farber Cancer Institute. Serious Illness Conversation Guide. 2015. Updated February 2016. Accessed April 30, 2026. https://www.instituteforhumancaring.org/documents/Providers/Serious-Illness-Guide-old.pdf​
  19. 19.Berkey FJ, et al. Delivering bad or life-altering news. Am Fam Physician. 2018;98(2):99-104.
  20. 20.Jo A, et al. Health care use among cancer patients with diabetes, National Health and Nutrition Examination Survey, 2017–2020. Prev Chronic Dis. 2024;21:E58.
  21. 21.Shouman M, et al. Perioperative management of patients with diabetes and cancer. Cancers (Basel). 2024;16(16):2821.
  22. 22.Shahid RK, et al. Diabetes and cancer. Cancers (Basel). 2021;13(22):5735.
  23. 23.Psarakis HM. Clinical challenges in caring for patients with diabetes and cancer. Diabetes Spectr. 2006;19(3):157-162.
  24. 24.Joint British Diabetes Societies for Inpatient Care. The management of glycaemic control in people with cancer. January 2023. Accessed May 1, 2026. https://abcd.care/sites/default/files/site_uploads/JBDS_Guidelines_Current/JBDS_17_Oncology_Guideline_with_QR_code_January_2023.pdf​
  25. 25.Anker SD, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461.
  26. 26.Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232.
  27. 27.McDonald ES, et al. Association of GLP-1 agonists with breast cancer incidence in women. J Clin Oncol. 2026;44(16):10506.
  28. 28.Dai H, et al. GLP-1 receptor agonists and cancer risk in adults with obesity. JAMA Oncol. 2025;11(10):1186-1193.
  29. 29.Florido R, et al. Cardiovascular disease risk among cancer survivors. J Am Coll Cardiol. 2022;80(1):22-32.
  30. 30.Mulder FI, et al. Risk of cardiovascular disease in cancer survivors after systemic treatment. JACC Cardiooncol. 2025;7(4):360-378.
  31. 31.Alexandre J, et al. Cardiovascular toxicity related to cancer treatment. J Am Heart Assoc. 2020;9(18):e018403.
  32. 32.National Comprehensive Cancer Network. Survivorship. NCCN clinical practice guidelines in oncology. Accessed July 7, 2026. https://www.nccn.org/professionals/physician_gls/pdf/survivorship.pdf​
  33. 33.Ligibel JA, et al. Exercise, diet, and weight management during cancer treatment. J Clin Oncol. 2022;40(22):2491-2507.
  34. 34.Rock CL, et al. American Cancer Society nutrition and physical activity guideline for cancer survivors. CA Cancer J Clin. 2022;72(3):230-262.
  35. 35.Arnett DK, et al. ACC/AHA guideline on the primary prevention of cardiovascular disease. J Am Coll Cardiol. 2019;74(10):1429-1430.
  36. 36.Kuderer NM, et al. Mitigating acute chemotherapy-associated adverse events in patients with cancer. Nat Rev Clin Oncol. 2022;19(11):681-697.
  37. 37.Lustberg MB, et al. Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. Nat Rev Clin Oncol. 2023;20(8):527-542.
  38. 38.Kamboj M, et al. Vaccination of adults with cancer: ASCO guideline. J Clin Oncol. 2024;42(14):1699-1721.
  39. 39.Basak D, et al. Comparison of anticancer drug toxicities: paradigm shift in adverse effect profile. Life (Basel). 2021;12(1):48.
  40. 40.Bishara GG, et al. Immunological consequences of chemotherapy. J Immunother Cancer. 2026;14(5):e014099.
  41. 41.Zhu N, et al. Bone complications of cancer treatment. Cancer Treat Rev. 2024;130:102828.
  42. 42.Shapiro CL, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol. 2019;37(31):2916-2946.
  43. 43.Zheng H, et al. Trastuzumab-induced cardiotoxicity: when and how much should we worry?. JCO Oncol Pract. 2024;20(8):1055-1063.
  44. 44.LeVee A, et al. New drugs, new toxicities. Am Soc Clin Oncol Educ Book. 2025;45(3):e473384.
  45. 45.Sarmento ACA, et al. Genitourinary syndrome of menopause. Front Reprod Health. 2021;3:779398.
  46. 46.Dugan CL, et al. Genitourinary syndrome of menopause in cancer survivors. Clin Obstet Gynecol. 2024;67(1):89-100.
  47. 47.Shivam K, et al. Management of bone health in breast cancer survivors. JCO Oncol Pract. Published online June 10, 2026. Accessed August 11, 2026. https://ascopubs.org/doi/abs/10.1200/OP-26-00169​
  48. 48.Okwuosa TM, et al. Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system. Circ Genom Precis Med. 2021;14(3):e000082.
  49. 49.Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339(22):1609-1618.
  50. 50.Dent SF, et al. Aromatase inhibitor therapy. Breast Cancer Res Treat. 2011;126(2):295-310.
  51. 51.Mortimer JE. Managing the toxicities of the aromatase inhibitors. Curr Opin Obstet Gynecol. 2010;22(1):56-60.
  52. 52.National Comprehensive Cancer Network. Prostate cancer. NCCN clinical practice guidelines in oncology. Accessed July 7, 2026. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf​
  53. 53.Raychaudhuri R, et al. Prostate cancer. JAMA. 2025;333(16):1433-1446.
  54. 54.McKeown D, et al. Radiation proctitis. StatPearls. Accessed July 7, 2026. https://www.ncbi.nlm.nih.gov/books/NBK559295/​
  55. 55.Children's Oncology Group. Long-term follow-up guidelines. Accessed July 7, 2026. https://childrensoncologygroup.org/wp-content/uploads/2026/05/COG_LTFU_Guidelines_Only_v6.pdf​
  56. 56.Zhang D, et al. Metabolic/endocrine disorders in survivors of childhood-onset and cranial radiotherapy-treated ALL/NHL: a meta-analysis. Reprod Biol Endocrinol. 2023;21(1):91.
  57. 57.Baumann BC, et al. Comparative effectiveness of proton vs photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer. JAMA Oncol. 2020;6(2):237-246.
  58. 58.Coderre D, et al. Cancer prehabilitation in practice: the current evidence. Curr Oncol Rep. 2022;24(11):1569-1577.
  59. 59.American Academy of Family Physicians. Pre- and post-operative care. Policies. October 2023. Accessed May 1, 2026. https://www.aafp.org/about/policies/all/pre-post-operative-care.html
  60. 60.Higdon ML, et al. Oncologic emergencies: recognition and initial management. Am Fam Physician. 2018;97(11):741-748.
  61. 61.Brahmer JR, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy. J Clin Oncol. 2018;36(17):1714-1768.
  62. 62.Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073-4126.
  63. 63.National Comprehensive Cancer Network. Management of immune checkpoint inhibitor-related toxicities. Accessed July 7, 2026. https://www.nccn.org/professionals/physician_gls/pdf/ici_tox.pdf​
  64. 64.Yabroff KR, et al. Financial hardship following a cancer diagnosis: a family matter. Am Fam Physician. 2024;110(5):457-459.
  65. 65.Andersen BL, et al. Management of anxiety and depression in adult survivors of cancer. J Clin Oncol. 2023;41(18):3426-3453.
  66. 66.Kulchycki M, et al. Aerobic physical activity and depression among patients with cancer. JAMA Netw Open. 2024;7(10):e2437964.
  67. 67.Desmarais JE, et al. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry. 2009;70(12):1688-1697.
  68. 68.Sweegers MG, et al. Which exercise prescriptions improve quality of life and physical function in patients with cancer during and following treatment. Br J Sports Med. 2018;52(8):505-513.
  69. 69.Takemura N, et al. The effects of physical activity on overall survival among advanced cancer patients. BMC Cancer. 2021;21(1):242.
  70. 70.Nicoletti B, et al. Combining a wellness visit with a problem-oriented visit: a coding guide. Fam Pract Manag. 2022;29(1):15-20.
  71. 71.Millette KW. Tips for time-based coding. Getting Paid blog. October 31, 2022. Accessed May 1, 2026. https://www.aafp.org/pubs/fpm/blogs/gettingpaid/entry/emcoding-series-part-two.html​
  72. 72.Wu V, et al. G2211 Update and infographic: when to use the visit complexity add-on code. Fam Pract Manag. 2025;32(1):13-15.
  73. 73.Smith GF, et al. Primary care of the patient with cancer. Am Fam Physician. 2007;75(8):1207-1214.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.